Geron Corporation (GERN)

$3.73

+0.05

(+1.36%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Geron Corporation

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 164.0K → 23.0K (in $), with an average decrease of 86.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -44.80M → -51.97M (in $), with an average decrease of 16.0% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 94.8%

Performance

  • $3.65
    $3.87
    $3.73
    downward going graph

    2.28%

    Downside

    Day's Volatility :5.69%

    Upside

    3.49%

    downward going graph
  • $1.64
    $4.05
    $3.73
    downward going graph

    56.03%

    Downside

    52 Weeks Volatility :59.51%

    Upside

    7.9%

    downward going graph

Returns

PeriodGeron CorporationSector (Health Care)Index (Russel 2000)
3 Months
95.74%
-0.7%
0.0%
6 Months
107.91%
6.6%
0.0%
1 Year
76.92%
3.7%
-1.5%
3 Years
162.86%
14.0%
-21.8%

Highlights

Market Capitalization
2.1B
Book Value
$0.46
Earnings Per Share (EPS)
-0.32
PEG Ratio
-2.38
Wall Street Target Price
5.08
Profit Margin
0.0%
Operating Margin TTM
-236039.14%
Return On Assets TTM
-41.47%
Return On Equity TTM
-112.29%
Revenue TTM
237.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-77.7%
Gross Profit TTM
-93.7M
EBITDA
-193.5M
Diluted Eps TTM
-0.32
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.33
EPS Estimate Next Year
-0.17
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Geron Corporation(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 36.19%

Current $3.73
Target $5.08

Company Financials

FY18Y/Y Change
Revenue
1.1M
↑ 0.09%
Net Income
-27.0M
↓ 3.22%
Net Profit Margin
-2.5K%
↑ 86.79%
FY19Y/Y Change
Revenue
460.0K
↓ 56.85%
Net Income
-63.6M
↑ 135.23%
Net Profit Margin
-13.8K%
↓ 11281.0%
FY20Y/Y Change
Revenue
253.0K
↓ 45.0%
Net Income
-75.6M
↑ 18.98%
Net Profit Margin
-29.9K%
↓ 16069.95%
FY21Y/Y Change
Revenue
1.4M
↑ 450.59%
Net Income
-121.0M
↑ 59.97%
Net Profit Margin
-8.7K%
↑ 21202.54%
FY22Y/Y Change
Revenue
596.0K
↓ 57.21%
Net Income
-141.0M
↑ 16.6%
Net Profit Margin
-23.7K%
↓ 14980.42%
FY23Y/Y Change
Revenue
237.0K
↓ 60.23%
Net Income
-184.1M
↑ 30.56%
Net Profit Margin
-77.7K%
↓ 54027.46%
Q3 FY22Q/Q Change
Revenue
297.0K
↑ 306.85%
Net Income
-40.8M
↑ 44.48%
Net Profit Margin
-13.7K%
↑ 24963.46%
Q4 FY22Q/Q Change
Revenue
103.0K
↓ 65.32%
Net Income
-42.4M
↑ 3.87%
Net Profit Margin
-41.2K%
↓ 27424.74%
Q1 FY23Q/Q Change
Revenue
21.0K
↓ 79.61%
Net Income
-38.1M
↓ 10.22%
Net Profit Margin
-181.3K%
↓ 140133.89%
Q2 FY23Q/Q Change
Revenue
29.0K
↑ 38.1%
Net Income
-49.2M
↑ 29.29%
Net Profit Margin
-169.7K%
↑ 11556.48%
Q3 FY23Q/Q Change
Revenue
164.0K
↑ 465.52%
Net Income
-44.8M
↓ 8.98%
Net Profit Margin
-27.3K%
↑ 142428.16%
Q4 FY23Q/Q Change
Revenue
23.0K
↓ 85.98%
Net Income
-52.0M
↑ 16.0%
Net Profit Margin
-226.0K%
↓ 198653.79%
FY18Y/Y Change
Total Assets
185.3M
↑ 67.96%
Total Liabilities
7.6M
↑ 15.88%
FY19Y/Y Change
Total Assets
165.5M
↓ 10.67%
Total Liabilities
30.4M
↑ 302.09%
FY20Y/Y Change
Total Assets
270.7M
↑ 63.57%
Total Liabilities
59.8M
↑ 96.89%
FY21Y/Y Change
Total Assets
226.0M
↓ 16.51%
Total Liabilities
99.6M
↑ 66.64%
FY22Y/Y Change
Total Assets
190.6M
↓ 15.69%
Total Liabilities
110.6M
↑ 11.0%
FY23Y/Y Change
Total Assets
394.1M
↑ 106.78%
Total Liabilities
146.1M
↑ 32.15%
Q3 FY22Q/Q Change
Total Assets
232.6M
↓ 2.33%
Total Liabilities
124.4M
↑ 29.47%
Q4 FY22Q/Q Change
Total Assets
190.6M
↓ 18.07%
Total Liabilities
110.6M
↓ 11.14%
Q1 FY23Q/Q Change
Total Assets
424.9M
↑ 122.94%
Total Liabilities
98.8M
↓ 10.63%
Q2 FY23Q/Q Change
Total Assets
415.3M
↓ 2.26%
Total Liabilities
116.9M
↑ 18.26%
Q3 FY23Q/Q Change
Total Assets
413.0M
↓ 0.55%
Total Liabilities
122.4M
↑ 4.74%
Q4 FY23Q/Q Change
Total Assets
394.1M
↓ 4.59%
Total Liabilities
146.1M
↑ 19.38%
FY18Y/Y Change
Operating Cash Flow
-21.0M
↑ 2.2%
Investing Cash Flow
-77.7M
↓ 438.35%
Financing Cash Flow
93.0M
↑ 8267.96%
FY19Y/Y Change
Operating Cash Flow
-43.8M
↑ 108.62%
Investing Cash Flow
27.4M
↓ 135.26%
Financing Cash Flow
19.5M
↓ 79.03%
FY20Y/Y Change
Operating Cash Flow
-66.7M
↑ 52.07%
Investing Cash Flow
-105.3M
↓ 484.38%
Financing Cash Flow
168.3M
↑ 763.36%
FY21Y/Y Change
Operating Cash Flow
-95.6M
↑ 43.37%
Investing Cash Flow
71.9M
↓ 168.31%
Financing Cash Flow
48.6M
↓ 71.16%
FY22Y/Y Change
Operating Cash Flow
-127.4M
↑ 33.3%
Investing Cash Flow
62.1M
↓ 13.73%
Financing Cash Flow
87.3M
↑ 79.72%
Q3 FY22Q/Q Change
Operating Cash Flow
-29.6M
↑ 3.28%
Investing Cash Flow
9.8M
↑ 250.25%
Financing Cash Flow
4.8M
↓ 93.23%
Q4 FY22Q/Q Change
Operating Cash Flow
-35.2M
↑ 18.93%
Investing Cash Flow
19.0M
↑ 92.93%
Financing Cash Flow
11.9M
↑ 149.54%
Q1 FY23Q/Q Change
Operating Cash Flow
-46.4M
↑ 31.79%
Investing Cash Flow
-178.7M
↓ 1041.29%
Financing Cash Flow
281.0M
↑ 2257.18%
Q2 FY23Q/Q Change
Operating Cash Flow
-29.6M
↓ 36.16%
Investing Cash Flow
-44.4M
↓ 75.13%
Financing Cash Flow
18.3M
↓ 93.47%
Q3 FY23Q/Q Change
Operating Cash Flow
-50.8M
↑ 71.75%
Investing Cash Flow
-4.7M
↓ 89.39%
Financing Cash Flow
29.4M
↑ 60.05%

Technicals Summary

Sell

Neutral

Buy

Geron Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Geron Corporation
Geron Corporation
15.91%
107.91%
76.92%
162.86%
107.91%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Geron Corporation
Geron Corporation
NA
NA
-2.38
-0.33
-1.12
-0.41
NA
0.46
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Geron Corporation
Geron Corporation
Buy
$2.1B
107.91%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • RA Capital Management, LLC

    7.86%
  • BlackRock Inc

    7.17%
  • Deep Track Capital, LP

    5.03%
  • Vanguard Group Inc

    4.86%
  • State Street Corporation

    4.36%
  • Vivo Capital, LLC

    4.11%

Corporate Announcements

  • Geron Corporation Earnings

    Geron Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.

Organization
Geron Corporation
Employees
141
CEO
Dr. John A. Scarlett M.D.
Industry
Health Technology

FAQs